跳至主要内容
临床试验/NCT06660641
NCT06660641已完成不适用

TaurolockTMHep100 Versus Saline 0.9% As Secondary Prevention of Catheter-related Bloodstream Infections (CRBSI); a Single Center, Double Blinded, Randomized, Controlled Study in Patients with Chronic Intestinal Failure Dependent on Home Parenteral Support (HPS)

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2019年6月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
61
试验地点
1
主要终点
Incidence of recurrent catheter-related bloodstream infections

研究概览

简要总结

The purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.

详细描述

Patients with long-term intestinal failure rely on Home Parenteral support (HPS) delivered through a central venous catheter(CVC). Catheter Related Blood Stream Infections(CRBSI) are a frequent complication leading to increased morbidity, hospital admissions, cost, and risk of repeated replacement of the CVC. The infections often originate from contamination of the catheter hub, and growth of microorganisms on the inner lumen of the catheter imbedded in a biofilm. To prevent infections good hygiene guidelines and the use of a catheter lock solution is applied.

The primary objective is to compare two catheter lock solutions, 1,35% taurolidine and 0.9% saline, on the occurence of recurrent CRBSIs. The secondary objectives are to compare the two devices according to other catheter-related complications, adverse events and costs.

Patients with at least one prior CRBSI is included. Patients instill the solution in their CVC after each infusion of HPS, with a minimum of three times per week, depending on their individual HPS programme.

Before the blinded randomization the patients will be paired according to age and stratified according to prior CRBSI incidence.

Duration of the instillation will be 24 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients receiving HPS at the department of Medical gastroenterology, Rigshospitalet, who have at least one prior CRBSI and thereby demonstrated susceptibility towards developing CRBSI while on HPS and the following:
  • •Signed informed consent form
  • •Has a single-lumen subcutaneously tunneled CVC
  • •Has been at least 3 weeks since termination of the antibiotic treatment for their last CRBSI

排除标准

  • •Patients who:
  • •have a known hypersensitivity/allergy to TauroLockTMHep 100 or heparin and/or their excipients
  • •are pregnant, lactating or nursing

研究组 & 干预措施

TaurolockTMHep100

Active Comparator

干预措施: TaurolockTMHep100 (Device)

0.9% saline

Placebo Comparator

干预措施: 0.9 % saline (Device)

结局指标

主要结局

Incidence of recurrent catheter-related bloodstream infections

时间窗: Treatment time 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Palle Bekker Jeppesen

MD, PhD, DMSc, Professor

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验

Clinical Trial Comparing TaurolockTMHep100... | 临床试验